• Molecular NameMecamylamine
  • Synonym2-Methylamino-2,3,3-trimethylnorbornane; 2-Methylaminoisocamphane; 3-Methylaminoisocamphane; 3-Methylaminoisocamphane hydrochloride; Mecamilamina; Mecamylamine Hydrochloride
  • Weight167.296
  • Drugbank_IDDB00657
  • ACS_NO60-40-2
  • Show 3D model
  • LogP (experiment)2.477
  • LogP (predicted, AB/LogP v2.0)2.57
  • pka11.3
  • LogD (pH=7, predicted)-0.5
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)0.78
  • LogSw (predicted, AB/LogsW2.0)1.38
  • Sw (mg/ml) (predicted, ACD/Labs)2.31
  • No.of HBond Donors1
  • No.of HBond Acceptors1
  • No.of Rotatable Bonds1
  • TPSA12.03
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA voltage dependent non-competitive antagonist at nicotinic receptors.
  • Absorption_valueN/A
  • Absorption (description)Mecamylamine is almost completely absorbed after oral administration; high concentrations are found in the liver and kidney.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding40.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionMore than 50% of a dose is excreted in 24 h as unchanged drug in acid urine; the excretion is reduced if the urine is alkaline.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityLabel side effects are listed below: Ileus, constipation, vomiting, nausea, anorexia, glossitis, dryness of mouth; orthostatic dizziness and syncope, postural hypotension; convulsions, choreiform movements, mental aberrations, tremor, paresthesias; intestitial pulmonary edema, fibrosis; urinary retention, impotence, decreased libido, weakness, fatigue, sedation.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A